Author

Anna Kagramanova

THE DEPENDENCE OF THE LEVEL OF GLYCOPROTEIN TYPE 2 ON THE LEVEL OF ZONULIN IN CROHN'S DISEASE
THE DEPENDENCE OF THE LEVEL OF GLYCOPROTEIN TYPE 2 ON THE LEVEL OF ZONULIN IN CROHN'S DISEASE

Anna Kagramanova  et al.

THE DEPENDENCE OF THE CONCENTRATION OF TYPE 2 GLYCOPROTEIN ON THE CONCENTRATION OF ZONULIN IN CROHN'S DISEASE DURING REMISSION OF THE DISEASE
THE DEPENDENCE OF THE CONCENTRATION OF TYPE 2 GLYCOPROTEIN ON THE CONCENTRATION OF ZONULIN IN CROHN'S DISEASE DURING REMISSION OF THE DISEASE

Anna Kagramanova  et al.

ZONULIN CONCENTRATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASESWITH AND WITHOUT COVID-19 INFECTION
ZONULIN CONCENTRATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASESWITH AND WITHOUT COVID-19 INFECTION

TREATMENT OF BONE MARROW MESENCHYMAL STROMAL CELLS REDUCES THE ACTIVITY ANKYLOSING SPONDYLITIS ASSOCIATED WITH CROHN'S DISEASE
TREATMENT OF BONE MARROW MESENCHYMAL STROMAL CELLS REDUCES THE ACTIVITY ANKYLOSING SPONDYLITIS ASSOCIATED WITH CROHN'S DISEASE

Anna Kagramanova  et al.

THE EFFECTIVENESS AND SAFENESS OF ALLOGENEIC MESENCHYMAL STROMAL CELLS OF BONE MARROW IN PATIENTS WITH REFRACTORY CROHN'S DISEASE - 10 YEARS OF OBSERVATION
THE EFFECTIVENESS AND SAFENESS OF ALLOGENEIC MESENCHYMAL STROMAL CELLS OF BONE MARROW IN PATIENTS WITH REFRACTORY CROHN'S DISEASE - 10 YEARS OF OBSERVATION

Anna Kagramanova  et al.

ZONULIN CONCENTRATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASESWITH AND WITHOUT COVID-19 INFECTION
ZONULIN CONCENTRATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASESWITH AND WITHOUT COVID-19 INFECTION

Anna Kagramanova  et al.

PREDICTOR OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH SEVERE ULCERATIVE COLITIS AND MEASURES FOR THEIR PREVENTION
PREDICTOR OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH SEVERE ULCERATIVE COLITIS AND MEASURES FOR THEIR PREVENTION

Anna Kagramanova  et al.

PREVALENCE OF GASTROINTESTINAL SYMPTOMS IN SARS-COV-2 INFECTION: RESULTS OF THE PROSPECTIVE CONTROLLED MULTINATIONAL GI-COVID19 STUDY
PREVALENCE OF GASTROINTESTINAL SYMPTOMS IN SARS-COV-2 INFECTION: RESULTS OF THE PROSPECTIVE CONTROLLED MULTINATIONAL GI-COVID19 STUDY

Anna Kagramanova  et al.

POST-INFECTION IRRITABLE BOWEL SYNDROME IN SARS-COV-2 PATIENTS: THE GI-COVID19 STUDY
POST-INFECTION IRRITABLE BOWEL SYNDROME IN SARS-COV-2 PATIENTS: THE GI-COVID19 STUDY

Anna Kagramanova  et al.

REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY
REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY

Anna Kagramanova  et al.

LARGE DIFFERENCES IN IBD CARE AND EDUCATION ACROSS EUROPE, FIRST RESULTS OF THE PAN-EUROPEAN VIPER SURVEY
LARGE DIFFERENCES IN IBD CARE AND EDUCATION ACROSS EUROPE, FIRST RESULTS OF THE PAN-EUROPEAN VIPER SURVEY

Anna Kagramanova  et al.

USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY
USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY

Anna Kagramanova  et al.

Item 1 - 12 / 12
1